BBOT
BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc. (BBOT) has 11 SEC Form 4 filings (14 transaction rows) in the rolling window, disclosed by 0 distinct insiders. Most recent filing: Jul 6, 2026.
- Industry:Biotechnology
- CEO:Eli Wallace
- Employees:62
- HQ:South San Francisco, CA, US
- IPO:2025-08-12
No open-market insider trades for BBOT (BridgeBio Oncology Therapeutics, Inc.) in the last 365 days.
Why this page may be quiet. Tracefour displays Form 4 open-market purchases (P) and sales (S): the two transaction codes that signal directional conviction. Restricted stock grants, option exercises, gifts, and tax-withholding sales are filed but intentionally not shown: they're disclosure mechanics, not buy/sell decisions.
Many large-cap executives trade through pre-scheduled 10b5-1 plans set months in advance and batch-disclosed each quarter, so the latest filing on EDGAR for a mega-cap can be weeks old without any insider actually choosing to trade in that window.
Related companies
BridgeBio Oncology Therapeutics, Inc. is in the Healthcare sector.